CurrentBlue Cross Blue Shield - IowaPolicy N/A

Cranial Electrotherapy Stimulation and Auricular Electrostimulation

This policy governs medical coverage determinations for cranial electrotherapy stimulation (CES) and electrical stimulation of auricular acupuncture points across a range of indications for Wellmark/Blue Cross and Blue Shield members in the payer's jurisdiction.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyCranial Electrotherapy Stimulation and Auricular Electrostimulation

Policy CodePolicy N/A

Change TypeNo material change — policy maintained as current

Effective DateOriginal Effective Date: October 2010

Next Review DateN/A

Key ActionIf requesting coverage, submit prior authorization with indication, prior/concurrent therapies, device type and regimen, and supporting trial data.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalCES stance

InvestigationalAuricular stance

Apr 2026Last review

11 RCTsCES RCTs (chronic pain)

0783T, A4543, A4596

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

CURRENTPolicy status

Coverage Determinations

Cranial Electrotherapy Stimulation

Covered status

CES coverage stance: Cranial electrotherapy stimulation is investigational in all situations because the evidence is insufficient to determine improvement in net health outcome.

Based on small sham-controlled RCTs and systematic reviews with heterogeneous results and methodological limitations (see indications: pain, psychiatric, insomnia, obesity, functional constipation).

Auricular Electrostimulation

Covered status

Auricular electrostimulation coverage stance: Electrical stimulation of auricular acupuncture points is investigational in all situations because the evidence is insufficient to determine improvement in net health outcome.

Based on limited trials, inconsistent results, and methodological limitations across indications including acute/chronic pain, obesity, and opioid withdrawal.

Evidence synthesis — pain and psychiatric indications

Evidence summary statements from systematic reviews and trials

Acute or chronic pain evidence: Systematic reviews and meta-analyses show mixed results: pooled analyses found marginal benefit for headache but a Cochrane meta-analysis of chronic pain (5 trials, N=270) found no significant difference versus sham; subsequent small sham-controlled trials reported inconsistent benefits and had methodologic limitations.

High-quality evidence is limited; additional trials needed.

Psychiatric/behavioral conditions evidence: Meta-analyses report reductions in anxiety and depression symptoms with CES versus control (effect sizes ranging from small to moderate), but heterogeneity in session number/duration, outcome measures, and small trial sizes limit confidence in pooled estimates.

References include Price et al (2021), Ching et al (2022), and Liu et al (2025).

Evidence-based findings

Evidence summary and trial findings (no explicit coverage decision text in this segment).

Meta-analyses: Multiple meta-analyses report small-to-moderate pooled reductions in anxiety and depression symptoms with CES versus sham, but with heterogeneity and limitations.

Price et al (2021); Ching et al (2022); Liu et al (2025).

Randomized trials — mixed results: Individual RCTs show mixed outcomes: some recent device trials (Flow FL-100, ProlivRx, OAK) reported benefit on primary endpoints or remission, whereas other trials (e.g., Alpha-Stim-D) did not show superiority to sham; trials vary in device, dosing, and populations.

Trial heterogeneity affects comparability.

Safety: Reported adverse events are generally minor (e.g., skin redness, irritation, trouble concentrating) though some device regimens had higher local adverse effects; no major safety signals reported in pooled analyses.

Examples: Flow FL-100 reported higher skin redness and irritation compared with sham.

Coverage conclusions

Summary coverage stance based on evidence in this section

Overall evidence conclusion: The evidence for CES does not support its use for depression, anxiety, Parkinson disease, smoking cessation, and tic disorders; additional evidence is needed to permit conclusions about benefit for anxiety or depression despite some positive RCTs with important limitations.

Derived from systematic reviews and RCT summaries indicating heterogeneity and methodological concerns.

Functional constipation trials: One single-center unblinded RCT (Gong et al) reported improvements in self-rated anxiety, depression, and constipation scores with CES plus biofeedback versus biofeedback alone, but the unblinded design and self-reported outcomes limit confidence in these findings.

Additional blinded, higher-quality trials needed.

Evidence-based conclusions

Evidence summaries and coverage-relevant conclusions

Functional Constipation - Evidence Conclusion: A single unblinded RCT reported improvements in anxiety, depression, and constipation scores with CES plus biofeedback, but high risk of bias limits the reliability of the result.

Gong et al (2016).

Obesity - Evidence Conclusion: A multicenter double-blind RCT (Modius Lean) did not find a significant difference in percent weight loss at 6 months between active and sham devices; some secondary measures (visceral adipose tissue) differed but overall clinical benefit was not demonstrated.

Viirre et al (2025). Additional trials required.

Evidence summaries for insomnia, acute pain, and chronic pain

Evidence-based findings summarized in this section — use these to inform coverage decisions

Insomnia evidence: A multicenter double-blind RCT (Modius Sleep) with 147 patients showed a statistically greater mean reduction in ISI for active device versus sham (-4.85 vs -3.14; p=0.010) but secondary outcomes were not significant and responder counts were not fully disclosed; clinical significance remains uncertain.

Curry et al (2024); Genesis Sleep had no direct clinical studies.

Acute pain evidence: Multiple small pilot RCTs of NSS-2 Bridge in postoperative settings reported lower pain scores than sham in some studies but results were inconsistent and sample sizes were small; adverse events included electrode discomfort and placement problems.

Ilfeld et al (2024) and others.

Chronic pain evidence: Small trials of auricular electrostimulation (P-Stim and related devices) for chronic low back pain, cervical pain, and rheumatoid arthritis reported small improvements but were limited by small sample sizes and methodological weaknesses, leaving clinical importance uncertain.

Additional larger, rigorous RCTs needed.

Evidence summaries

Summary findings by indication

Obesity evidence summary: Randomized trials and systematic reviews of auricular electrostimulation for obesity have small sample sizes, heterogeneous protocols, and inconsistent results; clinical importance of reported differences is unclear.

Schukro et al (2014); Yeh et al (2015); systematic reviews.

Opioid withdrawal evidence summary: Evidence includes one RCT (NET device) showing greater reduction in COWS score at 1 hour with active stimulation versus sham and observational studies reporting rapid symptom reductions; limitations include small size, blinding concerns, and short follow-up.

Greenwald et al (2025); observational series (Kroening & Oleson, Miranda & Taca).

This policy may not apply to members covered under the Federal Employee Program (FEP). Benefit determinations for FEP participants are made by the Federal Employee Program and are outside the scope of this Wellmark policy; providers must verify individual member benefits and contract terms before proceeding.

The evidence base for cranial electrotherapy stimulation (CES) and auricular electrostimulation for chronic pain and psychiatric conditions is limited and inconsistent. A Cochrane review and pooled meta-analysis found no significant difference versus sham for chronic pain (meta-analysis of 5 trials, N=270), and systematic reviews/meta-analyses for anxiety and depression report heterogeneous results across small trials. Overall, trial heterogeneity (session number/duration, device, outcomes) and small sample sizes limit confidence in efficacy claims.

Within the cited sections there are no explicit standalone exclusion criteria listed that would automatically bar use of CES or auricular electrostimulation; instead the document summarizes evidence limitations and indicates investigational status based on insufficient or inconsistent evidence.

The available evidence does not support routine use of CES for several specific indications. Studies cited report no demonstrated benefit for Parkinson disease (no motor or psychological improvement), no benefit for smoking cessation (5-day CES trial), and no significant effect for tic disorders. Similarly, evidence for psychiatric indications (anxiety, depression) is mixed and insufficient to establish net health benefit.

Study selection for evidence synthesis excluded trials with duplicative or overlapping populations. Where multiple reports drew on the same or overlapping participant sets, those redundant data were removed to avoid double-counting in pooled assessments and narrative summaries.

No clinical studies were identified for the Genesis Sleep device in the cited material. The Genesis Sleep device’s marketing/clearance status was noted to be based on substantial equivalence to Modius Sleep, rather than direct clinical trial evidence for Genesis Sleep itself.

Clinical-input received in 2011 from specialty societies and academic medical centers concluded that auricular electrostimulation should be considered investigational. This reviewer input contributed to the policy’s investigational classification for auricular electrostimulation.

The 2011 external input summarizes consensus views from three physician specialty societies and five academic medical centers that auricular electrostimulation is investigational. This historical clinical input supports the policy position that such interventions lack sufficient evidence for routine coverage.

A Cochrane-style meta-analysis and subsequent summaries for chronic pain showed no significant benefit of CES versus sham in pooled data (5 trials, N=270). Given these findings, CES for chronic pain is not supported by high-quality pooled evidence and therefore does not meet standards for established clinical benefit.

High-quality randomized trials, including the multi-center Alpha-Stim-D RCT, did not demonstrate superiority of active CES over sham on the primary depression outcome (difference not statistically significant). Several rigorous trials have shown no between-group benefit, which supports maintaining an investigational classification in the absence of consistent positive findings.

Based on the evidence reviewed, use of CES or auricular electrostimulation is considered not medically necessary for the following indications: Parkinson disease, smoking cessation, tic disorders, anxiety, and depression, as the current literature does not demonstrate consistent, clinically meaningful benefit for these conditions.

Randomized trials and systematic reviews evaluating auricular electrostimulation for obesity have produced inconsistent results and methodological heterogeneity. One multicenter RCT of a vestibular/auricular device did not show a clinically meaningful difference in weight loss versus sham, and systematic reviews report small, variable trials — therefore available evidence does not support clinical effectiveness for weight loss.

Auricular electrostimulation for acute or chronic pain is supported only by small trials with inconsistent results; several pilot postoperative studies reported lower pain scores but differences were not uniformly significant and chronic pain studies were limited by small samples and methodological issues. Consequently, the evidence is insufficient to conclude that auricular electrostimulation improves pain outcomes.

Trials and systematic reviews of auricular electrostimulation for obesity report inconsistent findings, small sample sizes, and heterogeneous treatment protocols. These limitations collectively support a determination that effectiveness for obesity is unproven and do not justify routine coverage.

The 2011 reviewer input reiterates that auricular electrostimulation was considered investigational by consulted specialty societies and academic centers; that investigational classification is reinforced here and supports noncoverage in the absence of stronger evidence.

Procedure, Supply, and DME Codes

Codes table referencedmixed

No codes listed

Regulatory / device K numbers listedmixed

K200636	AXUS ES-5 Electro- Acupuncture Device
K211971	Drug Relief V1
K201873	Sparrow Therapy System
K173861	Drug Relief
K170391	Ansistem-Pp
K152571	Stivax System
K141168	ANSiStim®
K133980	Pantheon Electrostimulator
K140530	Electro Auricular Device
K140788	P-Stim

1–10 of 19

1/2

Procedure CPTCPTCovered

0783T

Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment.

HCPCS suppliesHCPCSCovered

A4543	Supplies for transcutaneous electrical nerve stimulator, for nerves in the auricular region, per month.
A4596	Cranial electrotherapy stimulation (CES) system supplies and accessories, per month.

Durable Medical Equipment (DME)HCPCSCovered

E1399	Miscellaneous durable medical equipment.
E0721	Transcutaneous electrical nerve stimulator for nerves in the auricular region.
E0732	Cranial electrotherapy stimulation (CES) system, any type.

Other servicesHCPCSCovered

S8930

Electrical stimulation of auricular acupuncture points; each 15 minutes of personal one-on-one contact with the patient.

Prior Authorization, Documentation, and Billing Guidance

Note

Benefit verification

Prior approval is not required at the policy level; however, benefit verification is required because coverage depends on contract language and any applicable exclusions. Verify member benefits and contract terms before initiating treatment.

Verify member benefits and contract exclusions prior to service authorization or claims submission.

Prior Authorization

Prior authorization — justification and investigational status

Prior authorization is recommended when proposing cranial electrotherapy stimulation (CES) or auricular electrostimulation because these therapies are considered investigational in all situations and evidence is limited or mixed. When requesting prior authorization, the provider must justify CES or auricular electrostimulation as an alternative or adjunctive therapy to standard treatments and document the target condition and clinical rationale for use.

State the target condition (e.g., major depressive disorder, anxiety disorder, functional constipation, obesity, insomnia, acute or chronic pain, opioid withdrawal).

Background and Context

Background: Cranial electrotherapy stimulation (CES) delivers low‑intensity pulsed electrical current to the earlobes, mastoid processes, or scalp using external devices. CES and auricular electrostimulation are proposed to modulate neural activity implicated in pain, sleep, and mood disorders, but clinical trials and systematic reviews to date provide mixed and generally limited evidence for benefit, leading to investigational classifications in the policy.

Definitions and Device/Term Glossary

Cranial electrotherapy stimulation (CES) — definition and examples

DefinitionCranial electrotherapy stimulation (CES) delivers weak pulses of electrical current to the earlobes, mastoid processes, or scalp (also called cranial electrical stimulation or transcranial electrical stimulation).

Typical delivery sitesEarlobes, mastoid processes, scalp (via clip electrodes or scalp/behind-ear placements).

Common device exampleAlpha‑Stim (pulsed low‑intensity current via clip electrodes).

Other device contextsDevices may place electrodes on eyelids, frontal scalp, or behind the ears and are administered once or twice daily for days to weeks.

Indications under evaluationPain, insomnia, depression, anxiety, and functional constipation as described in clinical evidence summaries.

Care Setting and Level-of-Care Guidance

Outpatient/ambulatory device-based treatment

Top-level nodes for ambulatory device-based treatment

Opioid withdrawal candidate: Individuals undergoing rapid opioid discontinuation or experiencing opioid withdrawal symptoms; studies included patients meeting DSM-IV criteria for opioid dependence and those undergoing rapid discontinuation.

Evidence includes NET device RCT and observational studies; monitoring and short-term follow-up were typical.

Device and Treatment Modality Details

Cranial electrotherapy stimulation

CES modalities summary: Cranial electrotherapy stimulation (CES) encompasses devices that deliver low-intensity pulsed electrical current to the earlobes, mastoid processes, or scalp and have been evaluated for pain, insomnia, obesity, functional constipation, and psychiatric disorders.

Evidence across indications is limited and heterogeneous.

Auricular electrostimulation

Auricular modalities summary: Auricular electrostimulation includes devices that apply electrical stimulation to auricular acupuncture points or auricular nerves and have been studied for acute/chronic pain, obesity, and opioid withdrawal.

Trials vary in device, placement, and duration; evidence is insufficient to establish net health benefit.

CES modality details

Policy Revision History

April 2026policy_reviewLatest

Annual review completed and policy renewed (policy history entry: April 2026).

April 2024policy_review

Annual review completed and policy renewed (policy history entry: April 2024).

October 2023policy_update

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyCranial Electrotherapy Stimulation and Auricular Electrostimulation

Policy CodePolicy N/A

Change TypeNo material change — policy maintained as current

Effective DateOriginal Effective Date: October 2010

Next Review DateN/A

Key ActionIf requesting coverage, submit prior authorization with indication, prior/concurrent therapies, device type and regimen, and supporting trial data.

SourceLink

On This Page

Explain why standard therapies are insufficient, contraindicated, not tolerated, or why CES is being considered as an adjunct.

If part of a step-therapy pathway, document prior trials of comparator therapies (see Comparator therapies).

Documentation Required

Device, regimen, and prior-treatment documentation

Because device type, regimen, and prior treatments influence expected outcomes, submit detailed device and usage information with any prior authorization request or clinical documentation.

Device make and model (e.g., Alpha-Stim, Flow FL-100, ProlivRx, Modius Lean, Modius Sleep, OAK/Fischer Wallace, NSS-2 Bridge, NET, P-Stim).
Regimen: stimulation parameters, session duration, frequency, total treatment duration, and adherence metrics (e.g., sessions/week, minutes/session, cumulative hours, device-recorded compliance).
Prior treatments: list prior/concurrent therapies tried (medications, psychotherapy, biofeedback, behavior modification, diet/exercise programs), durations, and documented response or intolerance.
For indications like obesity or insomnia, include baseline metrics (weight, BMI, body fat, Insomnia Severity Index) and for opioid withdrawal include baseline COWS score.

Prior Authorization

Prior authorization expectations when evidence limited

When evidence is limited or mixed for the requested indication, prior authorization is likely; submit trial-level evidence and credible comparative data to support clinical benefit. Absent convincing data, coverage may be denied as investigational.

Include randomized controlled trial data or credible comparative trials relevant to the device and indication.
If supportive evidence is limited to small pilots or observational studies, provide rationale for extrapolation to the member (clinical similarity, objective outcome measures).
If therapy is investigational for the indication, note that prior authorization may result in denial due to insufficient evidence.

Documentation Required

Evidence-based documentation expectations

Providers must submit supporting clinical documentation showing that the requested use meets medical necessity expectations. Documentation should be specific, evidence-based, and include validated outcome measures where applicable.

Provide randomized controlled trial (RCT) citations or high-quality comparative studies when available.
Summarize relevant trial parameters (population, device, regimen, comparator, duration, primary outcomes and results).
Attach device-specific trial data if asserting efficacy for that particular device.

Documentation Required

Supporting documentation recommended

Provide the following supporting documentation with prior authorization or for clinical review to reduce denial risk due to insufficient evidence or incomplete records.

Trial data abstracts or full-text citations (RCTs, systematic reviews) relevant to the indication and device.
Detailed prior-therapy records, including dates, doses, duration, and outcomes (including intolerance or contraindications).
Symptom severity scores and validated outcome measures at baseline and after prior therapies (e.g., Hamilton Rating Scale for Depression, Beck Depression Inventory, Insomnia Severity Index, Wexner Constipation Score, COWS).
Device usage logs or adherence reports (device-recorded or patient logs).

Documentation Required

Documentation for functional constipation

For functional constipation cases where CES is proposed as an adjunct to biofeedback, prior authorization should include documentation that patients met Rome III criteria and were recommended for biofeedback; include baseline constipation scores and details of biofeedback therapy.

Document Rome III criteria fulfillment for functional constipation.
Confirm that biofeedback was recommended/attempted and include timing and response.
Provide baseline and follow-up Wexner Constipation Scores and any anorectal manometry results if performed.

Documentation Required

Required trial documentation and study parameters

When coverage is requested based on clinical trials, submit required trial documentation and study parameters so reviewers can assess applicability to the member.

Study device and manufacturer, dosing/regimen, session length and frequency, total treatment duration, and adherence thresholds used in trials (e.g., Flow FL-100: self-administered 30 minutes ≥5 times/day for 3 weeks then ≥3 times/day for 7 weeks).
Population eligibility criteria from trials (e.g., baseline symptom severity, stable concurrent therapy requirements).
Primary and secondary outcome measures and timepoints (e.g., HAM-D at 8 weeks, BDI at weeks 1–4, ISI at week 4).
Adverse event profile reported in trials and any device-specific safety signals (e.g., skin irritation with Flow FL-100).

Documentation Required

Required clinical documentation

For opioid withdrawal, acute pain, or chronic pain indications where outcome measures were used in trials, include specific clinical documentation and scoring to allow assessment of clinical benefit.

For opioid withdrawal: baseline and post-treatment COWS scores and timing (e.g., change at 1 hour), and whether opioid use disorder medications were used or requested.
For pain: baseline pain scores (e.g., numeric rating scale, VAS), analgesic consumption over defined periods, and device-related adverse events or discontinuations.
For psychiatric indications: baseline and follow-up scores on validated scales (HAM-D, BDI, SAI) and information about concurrent antidepressant or behavioral therapy use.

Denial Risk

Evidence limitations and potential denial risk for pain indications

Because evidence for pain indications is limited by small sample sizes and methodological limitations, anticipate potential denial risk and provide robust documentation if requesting coverage for pain management indications.

Submit trial design details, sample size, blinding credibility, and consistency of treatment effect across studies.
If only small pilot studies support benefit, include rationale for generalizability and any additional supportive observational data.

Billing Rule

Code reporting requirement and coding-based denial risk

When submitting claims, use the appropriate CPT, HCPCS, Revenue, and ICD diagnosis codes listed in the policy. Incomplete or imprecise coding may result in coding-based claim denial.

Report services with appropriate codes (examples in policy): CPT 0783T; HCPCS A4543, A4596, E0721, E0732; S8930 where applicable. Use correct ICD-10 diagnosis codes for the treated condition.
Attach prior authorization approval or clinical rationale when submitting claims to reduce risk of denial.

Step Therapy

Step therapy context and comparator-first consideration

Consider standard therapies and step-therapy context before CES or auricular electrostimulation. Many trials enrolled patients on stable pharmacotherapy or as adjuncts to standard care; document prior standard treatments and their outcomes.

Document trials of standard therapies (medication trials, psychotherapy, biofeedback, behavior modification, lifestyle interventions) including duration and response.
If step-therapy policies apply, ensure required comparators have been tried and document dates and outcomes.
For obesity or insomnia, confirm concurrent/dietary or sleep hygiene programs were provided per trial comparators.

Note

Comparator therapies

Comparator therapies commonly used in trials and relevant to prior authorization reviews include: medical management, psychotherapy/behavioral therapy, biofeedback, physical exercise, diet/lifestyle programs, opioid analgesics or opioid maintenance therapy (for opioid withdrawal), and standard pain management. Document which comparators were tried and patient response.

List comparators attempted (e.g., antidepressants, cognitive behavioral therapy, biofeedback, exercise, hypocaloric diet, opioid analgesics).
If comparing to sham-controlled trials, indicate whether the member’s planned use matches trial protocols (device, regimen, duration).

Auricular electrostimulation — definition and device examples

DefinitionAuricular electrostimulation applies electrical stimulation to auricular acupuncture points on the ear, often with ambulatory devices worn behind the ear over several days.

Device example — P‑StimP‑Stim: single‑use miniature stimulator worn behind the ear connecting to 3 acupuncture needles; preprogrammed on/off cycles (180 minutes on, 180 minutes off) with up to 96 hours battery life.

Device example — e‑pulsee‑pulse and similar auricular stimulators provide ambulatory electrical stimulation of ear acupuncture points for several days.

Typical regimenContinuous or scheduled stimulation over multiple days (e.g., single‑use P‑Stim cycles for up to 96 hours).

CES short definition (alternate chunk)

Short definitionCES: delivery of weak electrical pulses to the head (earlobes, mastoids, or scalp) using devices such as the Alpha‑Stim.

Also calledCranial electrical stimulation; transcranial electrical stimulation; electrical stimulation therapy.

Primary mechanism (proposed)Thought to modulate brain networks (hypothalamus, limbic system, reticular activating system).

Target populations — intended populations for CES/auricular stimulation

Primary target populationsIndividuals with acute or chronic pain (CES as alternative to or improvement on existing conservative therapies).

Behavioral/psychiatric targetsIndividuals with psychiatric, behavioral, or neurologic conditions under study (eg, depression, anxiety, insomnia).

Other evaluated populationsPatients with functional constipation, obesity, and those undergoing opioid withdrawal in auricular device studies.

CES definition (device examples)

CES (device examples)Alpha‑Stim (clip electrodes to earlobes), Fisher Wallace FW‑100, Flow FL‑100, ProlivRx, Modius Lean/Modius Sleep (vestibular/vestibular nerve stimulation devices).

Electrode placementsEarlobes, mastoid processes, frontal scalp, eyelids, or behind the ears depending on device design.

Typical regimens in trialsVaried by device — examples include 30–60 minutes/day up to multiple sessions per day or self‑administered schedules for weeks.

CES (abbreviation)

AbbreviationCES = Cranial Electrotherapy Stimulation

SynonymsCranial electrical stimulation; transcranial electrical stimulation; electrical stimulation therapy.

Usage in documentUsed throughout policy to refer to noninvasive low‑level electrical stimulation to head/ear regions.

RCT abbreviation definition

DefinitionRCT = Randomized Controlled Trial; denotes studies in which participants are randomly assigned to active or sham/control interventions.

ContextRCTs are the preferred evidence type referenced in the policy (multiple CES and auricular device RCTs summarized).

Acronym usageUsed in trial summaries and evidence syntheses throughout the document (eg, Alpha‑Stim‑D RCTs).

CES examples and device context (Modius, Alpha-Stim etc.)

Devices cited as examplesModius Lean/Modius Sleep, Alpha‑Stim, Flow FL‑100, ProlivRx, Fisher Wallace FW‑100, OAK (investigational).

Device contextThese examples appear in randomized controlled trials with device‑specific regimens (eg, Flow FL‑100: 30 minutes ≥5×/day then taper; ProlivRx: 40 min twice daily).

Regulatory/approval noteGenesis Sleep approval based on substantial equivalence to Modius Sleep; no direct clinical studies for Genesis Sleep were found.

Compliance definition used in obesity trial (>=5 hrs/week)

Compliance definition (obesity RCT)>=5 hours per week (used in Viirre et al. Modius Lean trial where both groups had 44% compliance).

ApplicationCompliance referred to device use time per week in the obesity trial comparing Modius Lean versus sham.

ImplicationAdherence defined this way affected interpretation of trial results and was reported in the policy evidence summary.

Auricular electrostimulation definition and device examples (Modius Sleep etc.)

DefinitionAuricular electrostimulation: application of electrical stimulation to auricular (ear) nerves or acupuncture points; devices may be worn behind the ear for continuous or multi‑day stimulation (eg, Modius Sleep, P‑Stim).

Device example — Modius SleepModius Sleep: electrical vestibular nerve stimulation used for insomnia (30 minutes/day in RCTs).

Device example — Modius Lean / P‑StimModius Lean (vestibular stimulation for obesity) and P‑Stim (single‑use auricular stimulator) are among devices evaluated for auricular or vestibular stimulation contexts.

Insomnia Severity Index (ISI) — definition and use as an outcome

DefinitionInsomnia Severity Index (ISI): a patient‑reported outcome measure used as the primary endpoint in insomnia trials; change in ISI was the primary outcome in the Modius Sleep RCT.

Scoring/usagePolicy reports mean change in ISI scores between active and sham groups (eg, Modius Sleep: -4.85 vs -3.14; p=0.010).

Interpretation noteNumber of patients achieving a clinically meaningful ISI decrease was not fully disclosed in the trial report; policy notes this limitation.

COWS — Clinical Opioid Withdrawal Scale definition

DefinitionCOWS = Clinical Opioid Withdrawal Scale; a 0–48 scale assessing opioid withdrawal severity with ranges: 5–12 = mild, 13–24 = moderate, 25–36 = moderately severe, >36 = severe.

Use in trialsUsed as the primary outcome in NET device RCT for opioid withdrawal (Greenwald et al.), with reported change in COWS at 1 hour post‑stimulation.

ReportingPolicy summarizes absolute and between‑group COWS score changes and proportions achieving clinically meaningful reductions.

Auricular electrostimulation (alternate chunk references)

Alternate referencesAuricular electrostimulation also described across multiple chunks including device‑level trial summaries and systematic reviews (see auricular device trial and review sections).

Device examples repeatedNSS‑2 Bridge, NET device, P‑Stim, Modius Sleep/Lean are referenced across trial and review summaries for auricular stimulation contexts.

Evidence contextPolicy notes small sample sizes and inconsistent results across auricular electrostimulation trials for pain, obesity, and opioid withdrawal.

0783T code definition

0783T description0783T — Transcutaneous auricular neurostimulation: set‑up, calibration, and patient education on use of equipment.

UseListed in the policy coding section for reporting provider services associated with transcutaneous auricular neurostimulation.

Coding contextProviders instructed to use appropriate CPT/HCPCS/DME/ICD codes as listed in the policy when submitting claims.

A4543 code definition

A4543 descriptionA4543 — Supplies for transcutaneous electrical nerve stimulator, for nerves in the auricular region, per month.

Billing contextListed under HCPCS supplies in the policy coding section for auricular region stimulator supplies.

FrequencyDescribed as a per‑month supplies code for auricular TENS‑type devices in the policy.

A4596 code definition

A4596 descriptionA4596 — Cranial electrotherapy stimulation (CES) system supplies and accessories, per month.

Billing contextListed under HCPCS supplies in the policy coding section for CES system supplies and accessories.

ApplicationIntended for monthly supply billing related to CES systems per the policy coding list.

E0721/E0732 DME code definitions

E0721 descriptionE0721 — Transcutaneous electrical nerve stimulator for nerves in the auricular region (DME).

E0732 descriptionE0732 — Cranial electrotherapy stimulation (CES) system, any type (DME).

Coding contextListed as durable medical equipment codes in the policy coding section for auricular and CES systems.

S8930 code definition

S8930 descriptionS8930 — Electrical stimulation of auricular acupuncture points; each 15 minutes of personal one‑on‑one contact with the patient.

Service contextListed under other services in the policy coding section for reporting time‑based auricular stimulation services.

Billing implicationIntended for reporting personal one‑on‑one auricular stimulation contact in 15‑minute increments per the policy listing.

CES device descriptions: Devices studied include Alpha-Stim, Flow FL-100, ProlivRx, Modius Lean, Modius Sleep, Fisher Wallace FW-100, and investigational devices (e.g., OAK); regimens and stimulation parameters vary across trials.

Heterogeneity in dose and duration complicates interpretation of pooled results.

CES devices

Device-specific notes: Recent randomized trials used device-specific self-administered regimens (examples: Alpha-Stim AID 1 hour/day for 8 weeks in some trials; Flow FL-100 multiple daily 30-minute sessions with tapering; ProlivRx 40 minutes twice daily for 8 weeks); adherence influenced outcomes in some studies.

Adherence and local adverse effects (e.g., skin redness with Flow FL-100) were reported.

CES modality (alternate chunk references)

CES alternate device notes: Clinical trial parameters and reported endpoints varied by device and study; some trials reported benefit in per-protocol or high-adherence subgroups but not in intent-to-treat analyses.

Examples include OAK and ProlivRx trials where adherence or subgroup analyses affected significance.

CES modality (device examples and recent trials)

Recent CES trials summary: Phase 2/3 randomized trials (e.g., Flow FL-100, ProlivRx, OAK) have reported mixed efficacy results across primary endpoints, with some demonstrating statistically significant differences and others not.

Safety profiles were generally acceptable with primarily minor device-related adverse events.

Auricular electrostimulation

Auricular modality details: Auricular modalities include transcutaneous and percutaneous devices (e.g., P-Stim, NET device, NSS-2 Bridge, Sparrow Ascent) with protocols ranging from brief perioperative application to continuous 5-day stimulation; indications studied include postoperative pain, chronic pain, obesity, and opioid withdrawal.

Device clearance status varies; NET and other devices have 510(k) clearances for specific indications such as opioid withdrawal.

Auricular electrostimulation devices (P-Stim, NET, NSS-2 Bridge)

Devices studied (P-Stim, NET, NSS-2 Bridge): Devices reported in trials include P-Stim (auricular stimulator), NET Device (NET Device™), and NSS-2 Bridge; study protocols and durations varied by device and indication.

NET Device randomized trial in opioid withdrawal and NSS-2 Bridge pilot studies reported in postoperative pain contexts.

Neuromodulation therapies overview

Neuromodulation therapies grouping: Modalities cited include cranial electrotherapy stimulation (CES), transcranial direct/alternating current stimulation (tDCS/tACS), auricular electrostimulation, and percutaneous auricular neuromodulation; these are related noninvasive neuromodulation approaches but have distinct evidence bases.

Policy focuses on CES and auricular electrostimulation; tDCS/tACS described as related modalities.

Policy revised and content moved from retired policy 'Electrical Stimulation for Treatment of Muscle Rehabilitation, Pain and Miscellaneous Conditions' (policy history entry: October 2023).